Therapy Area topics
Almost in stealth mode, Cytokinetics has pressed on with the heart failure project, which now awaits a key regulatory catalyst.
Central Nervous System
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Astrazeneca looks to enter a field in which Merck & Co recently tripped up, and in which Roche is the only IO player.
Phase 2 data could indicate whether the big pharma has a chance of disrupting Vertex’s monopoly.